Wave Life Sciences Announced What Could be Excellent News in Treating Duchenne Muscular Dystrophy

Wave Life Sciences

On March 26, 2025, Wave Life Sciences (WVE) announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, an exon skipping oligonucleotide being investigated in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

FORWARD-53 Trial demonstrates sustained and industry-leading exon . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.